Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279761 | 0.89 | HRH1 (0.56) | HRH1LOXL2CA2HRH4HRH3 | |
| SCHEMBL26116262 | 0.87 | HRH1 (0.54) | HRH1LOXL2CA2HRH4HRH3 | |
| SCHEMBL9164808 | 0.84 | NPC1 (0.50) | HRH1LOXL2CA2HRH4HRH3 | |
| SCHEMBL4444401 | 0.83 | HRH1 (0.59) | HRH1LOXL2CA2HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL28059639 | 0.81 | HRH1 (0.57) | HRH1LOXL2CA2HRH4HRH3 | |
| SCHEMBL271114 | 0.81 | HRH1 (0.63) | HRH1LOXL2CA2HRH4HRH3 | |
| SCHEMBL5540660 | 0.81 | HRH1 (0.63) | HRH1LOXL2CA2HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL7424038 | 0.79 | HRH1 (0.61) | HRH1LOXL2CA2HRH4HRH3 | |
| Methacrylic Acid SCHEMBL1921401 | 0.77 | CYP4A11 (0.42) | HRH1LOXL2CA2CYP4A11SMN1; SMN2 | |
| SCHEMBL346623 | 0.76 | SMN1; SMN2 (0.57) | HRH1LOXL2CA2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003535853-A | — | — | 2003-12-02 | — | — | JP | claimed |
| CN-1444572-A | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2003-09-24 | — | — | CN | claimed |
| EP-1299365-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | claimed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | claimed |
| WO-2001094325-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | HRH1 97/4885LOXL2 2230/4885CA2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.